Significance of divergent expression of prostaglandin EP4 and EP3 receptors in human prostate cancer

Molecular Cancer Research

Volumn 11, Issue 4, 2013, Pages 427-439

  Huang, Hosea F S ^a   Shu, Ping ^a   Murphy, Thomas F ^a   Aisner, Seena ^a   Fitzhugh, Valerie A ^a   Jordan, Mark L ^a,b  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE B; PROSTAGLANDIN E RECEPTOR 1; PROSTAGLANDIN E RECEPTOR 2; PROSTAGLANDIN E RECEPTOR 3; PROSTAGLANDIN E RECEPTOR 4; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR RUNX2;

ARTICLE; CELL CULTURE; CONTROLLED STUDY; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MIGRATION INHIBITION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION;

AGED; CELL MOVEMENT; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PHOSPHORYLATION; PROSTATIC NEOPLASMS; RECEPTORS, PROSTAGLANDIN E, EP3 SUBTYPE; RECEPTORS, PROSTAGLANDIN E, EP4 SUBTYPE;

EID: 84876533321     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-12-0464     Document Type: Article

References (50)

1. American Cancer Society. Cancer facts and figures 2011. Atlanta, GA: American Cancer Society, 2011.
2. Kolonel LN. Fat, meat, and prostate cancer. Epidemiol Rev 2001; 23:72-81. (Pubitemid 32906616)
3. Delfino RJ, Errini RL, Taylor TH, Howe S, Anton-Culver H. Demographic differences in prostate cancer incidence and stage: an examination of population diversity in California. Am J Prev Med 1998;14:96-102. (Pubitemid 28360943)
4. 2 increases growth and motility of colorectal carcinoma cells. J Biol Chem 2001;276:18075-81.
5. Harris SG, Padilla J, Koumas L, Ray D, Phipps RP. Prostaglandins as modulators of immunity. Trends Immunol 2002;23:144-50. (Pubitemid 34178297)
6. Cao Y, Prescott SM. Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J Cell Physiol 2000;190:279-86. (Pubitemid 34111968)
7. Garrison JB, Natasha Kyprianou N. Novel targeting of apoptosis pathways for prostate cancer therapy. Curr Cancer Drug Targets 2004;4:85-95. (Pubitemid 38332567)
8. Gupta S, Srivastava M, Ahmad N, Bostwick DG, Mukhtar H. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 2000;42:73-8. (Pubitemid 30004877)
9. Yoshimura R, Sano H, Masuda C, Kawamura M, Tsubouchi Y, Chargui J, et al. Expression of cyclooxygenase-2 in prostate carcinoma. Cancer 2000;89:589-96. (Pubitemid 30640105)
10. Shigemura K, Shirakawa T, Wada Y, Kamidono S, Fujisawa M, Gotoh A. Antitumor effects of etodolac, a selective cyclooxygenase-II inhibitor, against human prostate cancer cell lines in vitro and in vivo. Urology 2005;66:1239-44. (Pubitemid 41797298)
11. Roberts RO, Jacobson DJ, Girman CJ, Rhodes T, Lieber MM, Jacob-sen SJ. A population-based study of daily nonsteroidal anti-inflammatory drug use and prostate cancer. Mayo Clin Proc 2002;77:219-25. (Pubitemid 34177596)
12. 2 production. Transplantation 2000;70:1788-96. (Pubitemid 32064835)
13. Jordan ML, Hoffman RA, Debe EF, Simmons RL. In vitro locomotion of allosensitized T lymphocyte clones in response to metabolites of arachidonic acid is subset specific. J Immunol 1986;137:661-8. (Pubitemid 16045099)
14. 2 regulates tumor angiogenesis in prostate cancer. Cancer Res 2008;68:7750-9.
15. Breyer RM, Bagdassarian CK, Myers SA, Breyer MD. Prostanoid receptors: subtypes and signaling. Ann Rev Pharmacol Toxicol 2001;41:661-90. (Pubitemid 32385902)
16. Sugimoto Y, Narumiya S. Prostaglandin E receptors. J Biol Chem 2007;282:11613-7. (Pubitemid 47100657)
17. 2 receptor EP2 results in enhanced skin tumor development. Oncogene 2006;25:5507-16. (Pubitemid 44344101)
18. 2 receptor EP2 in esophageal squamous cell carcinoma. Ann Surg Oncol 2009;16:352-60.
19. Chell SD, Witherden IR, Dobson RR, Moorghen M, Herman AA, Qualtrough D, et al. Increased EP4 receptor expression in colorectal cancer progression promotes cell growth and anchorage independence. Cancer Res 2006;66:3106-13.
20. Robertson FM, Simeone AM, Lucci A, McMurray JS, Ghosh S, Cris-tofanilli M. Differential regulation of the aggressive phenotype of inflammatory breast cancer cells by prostanoid receptors EP3 and EP4. Cancer 2010;116:2806-14.
21. Kambe A, Yoshioka H, Kamitani H, Watanabe T, Baek SJ, Eling TE. The cyclooxygenase inhibitor sulindac sulfide Inhibits EP4 expression and suppresses the growth of glioblastoma cells. Cancer Prev Res 2009;2:1088-99.
22. Ma X, Kundu N, Rifat S, Walser T, Fulton AM. Prostaglandin E receptor EP4 antagonism inhibits breast cancer metastasis. Cancer Res 2006;66:2923-7.
23. Yang L, Huang Y, Porta R, Yanagisawa K, Gonzalez A, Segi E, et al. Host and direct antitumor effects and profound reduction in tumor metastasis with selective EP4 receptor antagonism. Cancer Res 2006;66:9665-72. (Pubitemid 44623666)
24. Kotani M, Tanaka I, Ogawa Y, Usui T, Tamura N, Mori K, et al. Structural organization of the human prostaglandin EP3 receptor subtype gene (PTGER3). Genomics 1997;40:425-34. (Pubitemid 27136995)
25. Dong Z, Bonfil RD, Chinni S, Deng X, Trindade Filho JC, Bernardo M, et al. Matrix metalloproteinase activity and osteoclasts in experimental prostate cancer bone metastasis tissue. Am J Pathol 2005;166:1173-86. (Pubitemid 40524441)
26. Akech J, Wixted JJ, Bedard K, van der Deen M, Hussain S, Guise TA, et al. Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions. Oncogene 2010;29:811-21.
27. 2 induced functional expression of early growth response factor-1 by EP4, but not EP2, prostanoid receptors via the phosphatidylinositol 3-kinase and extracellular signal-regulated kinases. J Biol Chem 2003;278:12151-6. (Pubitemid 36800194)
28. 2/EP4 receptor-evoked ERK activation. J Biol Chem 2004;279:29797-804. (Pubitemid 38915863)
29. 3 subtype isoforms expressed in human uterus. J Clin Endocrinol Metab 1995;85:4315-22. (Pubitemid 32055393)
30. 2 receptor transduce both intracellular calcium and cAMP signals. Biochemistry 1994;33:14496-502.
31. Wang W, Bergh A, Damber JE. Cyclooxygenase-2 expression correlates with local chronic inflammation and tumor neovascularization in human prostate cancer. Clin Cancer Res 2005;11:3250-6. (Pubitemid 40627872)
32. 2 and the protein kinase A pathway mediate arachidonic acid induction of c-fos in human prostate cancer cells. Br J Cancer 2000;82:2000-6. (Pubitemid 30326462)
33. Liu XH, Yao S, Kirschenbaum A, Levine AC. NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells. Cancer Res 1998;58:4245-9. (Pubitemid 28450018)
34. 2 receptors and clinicopatholog-ic features in human prostate cancer tissue. Urology 2006;68:1360-5. (Pubitemid 44880382)
35. Terada N, Shimizu Y, Kamba T, Inoue T, Maeno A, Kobayashi T, et al. Identification of EP4 as a potential target for the treatment of castration-resistant prostate cancer using a novel xenograft model. Cancer Res 2010;70:1606-15.
36. Huang HFS, Shu P, Murphy T, Jordan ML. Stable EP4 receptor knockdown inhibits prostate cancer growth in vivo [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 April 1-4; Chicago, Illinois. Philadelphia (PA): AACR; 2012.
37. 2-EP4 signaling initiates skin immune responses by promoting migration and maturation of Langerhans cells. Nat Med 2003;9:744-9. (Pubitemid 36749224)
38. Pratap J, Javed A, Languino LR, van Wijnen AJ, Stein JL, Stein GS, et al. The Runx2 osteogenic transcription factor regulates matrix metalloproteinase 9 in bone metastatic cancer cells and controls cell invasion. Mol Cell Biol 2005;25:8581-91. (Pubitemid 41369178)
39. Kang GH, Lee S, Lee HJ, Hwang KS. Aberrant CpG island hyper-methylation of multiple genes in prostate cancer and prostatic intrae-pithelial neoplasia. J Pathol 2004;202:233-40. (Pubitemid 38208661)
40. 2 regulates cellular migration via induction of vascular endo-thelial growth factor receptor-1 in HCA-7 human colon cancer cells. Biochem Pharmacol 2011;81:379-87.
41. 2-EP3 signaling regulates tumor-associated angiogenesis and tumor growth. J Exp Med 2003;197:221-32. (Pubitemid 36152316)
42. 3 deficiency modifies tumor outcome in mouse two-stage skin carcinogenesis. Carcinogenesis 2005;26: 2116-22. (Pubitemid 41672199)
43. 2 receptor subtypes, EP3 and EP4. J Biol Chem 2003;278:17977-81. (Pubitemid 36799405)
44. Meisdalen K, Olav F, Dajani O, Thoralf Christoffersen T, Dagny Sandnes D. Prostaglandins enhance epidermal growth factor-Induced DNA synthesis in hepatocytes by stimulation of E prosta-noid 3 and F prostanoid receptors. J Pharmacol Exp Ther 2007; 322:1044-50. (Pubitemid 47295800)
45. Ogawa Y, Suzuki T, Oikawa A, Hosono K, Kubo H, Amano H, et al.Bone marrow-derived EP3-expressing stromal cells enhance tumor-associated angiogenesis and tumor growth. Biochem Biophys Res Commun 2009;382:720-5.
46. Shoji Y, Takahashi M, Kitamura T, Watanabe K, Kawamori T, Maruyama T, et al. Down regulation of prostaglandin E receptor subtype EP3 during colon cancer development. Gut 2004;53: 1151-8. (Pubitemid 38961971)
47. Macias-Perez IM, Zent R, Carmosino M, Breyer MD, Breyer RM, Pozzi A. Mouse EP3 alpha, beta, and gamma receptor variants reduce tumor cell proliferation and tumorigenesis invivo. J BiolChem2008;283:12538-45.
48. Sanchez T, Moreno JJ. GR 63799X, an EP3 receptor agonist, induced S phase arrest and 3T6 fibroblast growth inhibition. Eur J Pharmacol 2006;529:16-23. (Pubitemid 43005280)
49. 2 receptor subtype 3. J Leuk Biol 2000;68:187-93.
50. Kirschenbaum A, Klausner AP, Lee R, Unger P, Yao S, Liu XH, et al. Expression of cyclooxygenase-1 and cyclooxygenase-2 in the human prostate. Urology 2000;56:671-6.